You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. COTS MMW Radar for Tracking Persons within a Security Perimeter

    SBC: PSQUAREDT LLC            Topic: HSB0121005

    The implications of the proposed investigations are that radar systems already implemented for the automotive industry can be exploited, adapted and optimized for this application. These radar systems are inexpensive, of small size, employ advanced processing techniques which allow the tracking of threat targets, transmit low average power (10 milliwatts) and are proven to be people safe. We will ...

    SBIR Phase I 2012 Department of Homeland Security
  2. Novel Biomarkers for Early Detection of Aspergillosis

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive aspergillosis (IA) caused by the fungus Aspergillus fumigatus is the most frequent fungal cause of death in immunocompromised patients. The number of patients at risk for developing IA is steadily increasing due to advances in medicine. Early and accurate diagnosis of IA is critical to patient outcome, yet is exceedingly difficult due to the lack of sp ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. CMV Therapeutic Vaccine for the Treatment of Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provi ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. A Quantitative Optical Sensor to Monitor Pre-Clinical Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Angiogenesis and hypoxia can significantly influence the efficacy of therapy and the behavior of surviving tumor cells. This important fact is supported by a vast amount of literature on pre-clinical models and clinical studies. There is growing demand for technologies to measure tumor hypoxia and angiogenesis temporally and spatially in vivo to enable advance ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Chronic Myelogenous Leukemia (CML) affects nearly 14,000 patients worldwide and is a disorder of the pluripotent hematopoietic stem cells with two distinct phases. The protracted myelopoliferative chronic phase is followed by a rapidly fatal blast crisis. In CML, a chromosomal translocation leads to production of the Philadelphia Chromosome (Ph1) in which the ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Measurement of Beta Cell Death in Diabetes

    SBC: L2 DIAGNOSTICS LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): All forms of diabetes are characterized by the death of insulin producing cells. In Type 1 diabetes (T1D), this leads to the reliance on exogenous insulin for survival. In addition, there is cell loss in T2D and inindividuals who lose islet or pancreas allografts. New therapies have been developed that can modulate the course of T1D but the effective appli ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Significant CT Radiation Dose Reduction with Equally Sloped Tomography

    SBC: TOMOSOFT TECHNOLOGIES, LLC            Topic: NIBIB

    DESCRIPTION (provided by applicant): CT has become a routine medical tool in diagnosis of diseases and visualization of critical interventional procedures. The number of CT examinations has significantly increased over the past two decades in the US, and reached approximately 72 million in 2007 alone [5,8]. According to the 2009 report from the National Council on Radiation Protection and Measurem ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel method for inhibiting diabetic retinopathy

    SBC: VASCULAR PHARMACEUTICALS            Topic: NEI

    DESCRIPTION (provided by applicant): The long-term objective of the proposed study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy. Insulin-like growth factor-I (IGF-I) has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease. However directly inhibiting the IGF-I receptor may be lead to neurotoxicity. Following ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. External Glaucoma Drainage Device

    SBC: CAMRAS VISION, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of blindness in the world affecting 67 million people. Reduction of intraocular pressure (IOP) is the only proven treatment for delaying the progression of vision loss caused by glaucoma. The current surgical options for IOP lowering are unpredictable and suboptimal in terms of success rate. One of the primary reasons for s ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government